顺铂诱导耳毒性的药物基因组学。
Pharmacogenomics of cisplatin-induced ototoxicity.
机构信息
Department of Surgery, Division of Otolaryngology, Southern Illinois University, School of Medicine, Springfield, IL, USA.
出版信息
Pharmacogenomics. 2011 Jul;12(7):1039-50. doi: 10.2217/pgs.11.48.
Abstract
Cisplatin ototoxicity affects different individuals in a widely variable manner. These variations are likely to be explained by genetic differences among those affected. It would be highly advantageous to identify genetic variants that predispose to cisplatin ototoxicity in order to minimize the risk to susceptible subgroups. Although this area of research is very important, only a few studies have rigorously examined the genetic basis for cisplatin-induced susceptibility to hearing loss. This article addresses recent progress in clarifying the incidence of cisplatin ototoxicity and the risk factors and controversies regarding the identification of genetic variants associated with cisplatin-induced hearing loss.
摘要
顺铂耳毒性对不同个体的影响差异很大。这些差异可能是由受影响个体之间的遗传差异引起的。如果能够识别出导致顺铂耳毒性的遗传变异，将有助于将这种风险最小化易感亚群。尽管这一研究领域非常重要，但只有少数研究严格检查了导致顺铂引起听力损失的遗传基础。本文介绍了阐明顺铂耳毒性的发生率以及与顺铂引起的听力损失相关的遗传变异体的风险因素和争议方面的最新进展。
相似文献
1
Pharmacogenomics of cisplatin-induced ototoxicity.顺铂诱导耳毒性的药物基因组学。
Pharmacogenomics. 2011 Jul;12(7):1039-50. doi: 10.2217/pgs.11.48.
2
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.TPMT 和 COMT 基因变异与接受顺铂化疗的儿童听力损失相关。
Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8.
3
Challenges in interpreting the evidence for genetic predictors of ototoxicity.遗传因素预测耳毒性的证据解读面临的挑战。
Clin Pharmacol Ther. 2013 Dec;94(6):631-5. doi: 10.1038/clpt.2013.178.
4
Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.顺铂诱导的小儿实体瘤耳毒性：谷胱甘肽S-转移酶和巨蛋白基因多态性的作用
J Pediatr Hematol Oncol. 2013 May;35(4):e138-43. doi: 10.1097/MPH.0b013e3182707fc5.
5
Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.TPMT和COMT基因变异对癌症患者顺铂所致听力损失的影响：两项新队列研究及一项荟萃分析揭示队列间存在显著异质性
PLoS One. 2014 Dec 31;9(12):e115869. doi: 10.1371/journal.pone.0115869. eCollection 2014.
6
TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.顺铂诱导耳毒性的儿科癌症患者中的硫嘌呤甲基转移酶、儿茶酚-O-甲基转移酶和酰基辅酶A结合蛋白2基因变异
Pharmacogenet Genomics. 2017 Jun;27(6):213-222. doi: 10.1097/FPC.0000000000000281.
7
[The analysis of the association of the polymorphic variants of the TPMT, COMT, and ABCC3 genes with the development of hearing disorders induced by the cisplatin treatment].[TPMT、COMT和ABCC3基因多态性变异与顺铂治疗所致听力障碍发生的相关性分析]
Vestn Otorinolaringol. 2018;83(4):60-66. doi: 10.17116/otorino201883460.
8
Genetic markers of cisplatin-induced hearing loss in children.儿童顺铂诱导性听力损失的遗传标志物。
Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.
9
Role of Cisplatin Dose Intensity and TPMT Variation in the Development of Hearing Loss in Children.顺铂剂量强度和 TPMT 变异在儿童听力损失发展中的作用。
Ther Drug Monit. 2023 Jun 1;45(3):345-353. doi: 10.1097/FTD.0000000000001085.
10
Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.硫代嘌呤甲基转移酶（TPMT）和儿茶酚-O-甲基转移酶（COMT）基因变异在顺铂所致耳毒性中的作用。
Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5.
引用本文的文献
1
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.顺铂化疗所致听力损失新型预测模型的开发与验证
J Clin Oncol. 2025 Jul;43(19):2173-2183. doi: 10.1200/JCO-24-01861. Epub 2025 May 5.
2
The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.遗传变异在顺铂放化疗导致的听力损失预测中的作用。
Cancer Med. 2024 Aug;13(16):e7465. doi: 10.1002/cam4.7465.
3
Rapamycin Perfluorocarbon Nanoparticle Mitigates Cisplatin-Induced Acute Kidney Injury.雷帕霉素全氟碳纳米颗粒减轻顺铂诱导的急性肾损伤。
Int J Mol Sci. 2023 Mar 23;24(7):6086. doi: 10.3390/ijms24076086.
4
Integrating pharmacogenomics into clinical trials of hearing disorders.将药物基因组学整合到听力障碍的临床试验中。
J Acoust Soc Am. 2022 Nov;152(5):2828. doi: 10.1121/10.0015092.
5
Cancer survivors and neurotoxic chemotherapy: hearing loss and tinnitus.癌症幸存者和神经毒性化疗：听力损失和耳鸣。
BMJ Support Palliat Care. 2023 Sep;13(3):345-353. doi: 10.1136/spcare-2022-003684. Epub 2022 Jul 27.
6
TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study.一项泛癌症生命研究表明，TCERG1L基因变异与儿童癌症患者顺铂诱导的听力损失有关。
NPJ Precis Oncol. 2021 Jul 14;5(1):64. doi: 10.1038/s41698-021-00178-z.
7
Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.顺铂化疗对内耳功能及血清耳声发射蛋白浓度的影响。
Eur Arch Otorhinolaryngol. 2022 Jun;279(6):2783-2789. doi: 10.1007/s00405-021-06967-3. Epub 2021 Jul 2.
8
[Screening for bilateral vestibulopathy in outpatients with unsteadiness].[对步态不稳门诊患者进行双侧前庭病筛查]
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021 Feb;35(2):116-119. doi: 10.13201/j.issn.2096-7993.2021.02.006.
9
Early Physiological and Cellular Indicators of Cisplatin-Induced Ototoxicity.顺铂诱导耳毒性的早期生理和细胞指标。
J Assoc Res Otolaryngol. 2021 Apr;22(2):107-126. doi: 10.1007/s10162-020-00782-z. Epub 2021 Jan 7.
10
GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs.GSTM1 缺失和 GSTT1 缺失：DPOAE 测量顺铂引起的急性耳毒性的预测因子。
J Mol Med (Berl). 2020 Jul;98(7):963-971. doi: 10.1007/s00109-020-01921-y. Epub 2020 May 20.
本文引用的文献
1
Platinum Compound-Related Ototoxicity in Children: Long-Term Follow-Up Reveals Continuous Worsening of Hearing Loss.儿童铂类化合物相关耳毒性：长期随访显示听力损失持续恶化
J Pediatr Hematol Oncol. 2004 Oct;26(10):649-655. doi: 10.1097/01.mph.0000141348.62532.73.
2
The design and screening of drugs to prevent acquired sensorineural hearing loss.用于预防获得性感觉神经性听力损失的药物的设计与筛选。
Expert Opin Drug Discov. 2011 May;6(5):491-505. doi: 10.1517/17460441.2011.562887. Epub 2011 Mar 15.
3
Screening of 38 genes identifies mutations in 62% of families with nonsyndromic deafness in Turkey.对38个基因进行筛查后发现，土耳其62%的非综合征性耳聋家庭存在突变。
Genet Test Mol Biomarkers. 2011 Jan-Feb;15(1-2):29-33. doi: 10.1089/gtmb.2010.0120. Epub 2010 Nov 30.
4
Genetic variants associated with cisplatin-induced hearing loss.与顺铂诱导的听力损失相关的基因变异。
Clin Genet. 2010 Jul;78(1):33-5. doi: 10.1111/j.1399-0004.2010.01414_2.x.
5
Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.有机阳离子转运体 2 介导顺铂诱导的耳肾毒性，是保护性干预的靶点。
Am J Pathol. 2010 Mar;176(3):1169-80. doi: 10.2353/ajpath.2010.090610. Epub 2010 Jan 28.
6
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.TPMT 和 COMT 基因变异与接受顺铂化疗的儿童听力损失相关。
Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8.
7
Cisplatin ototoxicity and protection: clinical and experimental studies.顺铂耳毒性及其防护：临床与实验研究。
Tohoku J Exp Med. 2009 Nov;219(3):177-86. doi: 10.1620/tjem.219.177.
8
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.有机阳离子转运体2（OCT2）在顺铂诱导的肾毒性中的作用。
Clin Pharmacol Ther. 2009 Oct;86(4):396-402. doi: 10.1038/clpt.2009.139. Epub 2009 Jul 22.
9
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.ERCC2基因的常见变异与骨肉瘤患者对顺铂化疗的反应及临床结局相关。
Pharmacogenomics J. 2009 Oct;9(5):347-53. doi: 10.1038/tpj.2009.19. Epub 2009 May 12.
10
Linkage disequilibrium between two high-frequency deletion polymorphisms: implications for association studies involving the glutathione-S transferase (GST) genes.两个高频缺失多态性之间的连锁不平衡：对涉及谷胱甘肽-S转移酶（GST）基因的关联研究的影响。
PLoS Genet. 2009 May;5(5):e1000472. doi: 10.1371/journal.pgen.1000472. Epub 2009 May 8.
Zotero 插件